Lewis y tetrasaccharide

Lewis Y tetrasaccharide (Lewis Y, LeY) is a tetrasaccharide derivative form of Lewis X trisaccharide (HY-N10534) . Lewis Y tetrasaccharide is an antigen associated with malignant ovarian carcinomas metastasis and poor prognosis[1][2].

Product Specifications

CAS Number

[82993-43-9]

Product Name Alternative

Lewis y

UNSPSC

12352005

Target

FAK

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Purity

99.64

Solubility

H2O : 125 mg/mL (ultrasonic)

Smiles

O[C@@H]([C@@H]([C@@H]([C@@H](O1)C)O)O)[C@@H]1O[C@H]([C@H](C=O)NC(C)=O)[C@@H]([C@H](O)CO)O[C@H]2[C@@H]([C@H]([C@H]([C@H](O2)CO)O)O)O[C@H]3[C@H]([C@@H]([C@@H]([C@@H](O3)C)O)O)O

Molecular Formula

C26H45NO19

Molecular Weight

675.63

References & Citations

[1]Yan LM, et al. Enhancement of the adhesive and spreading potentials of ovarian carcinoma RMG-1 cells due to increased expression of integrin alpha5beta1 with the Lewis Y-structure on transfection of the alpha1,2-fucosyltransferase gene. Biochimie. 2010 Jul;92 (7) :852-7. |[2]Yan L, et al. Lewis y enhances CAM-DR in ovarian cancer cells by activating the FAK signaling pathway and upregulating Bcl-2/Bcl-XL expression. Biochimie. 2015 Jun;113:17-25.